SXTC
NASDAQ · Pharmaceuticals
China Sxt Pharmaceuticals In
$1.73
+0.07 (+4.22%)
Financial Highlights (FY 2026)
Revenue
175.76M
Net Income
-333,524,860
Gross Margin
21.1%
Profit Margin
-189.8%
Rev Growth
-12.5%
D/E Ratio
0.05
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 21.1% | 21.1% | 67.2% | 67.2% |
| Operating Margin | -154.0% | -138.6% | 22.1% | 21.0% |
| Profit Margin | -189.8% | -180.3% | 15.9% | 16.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 175.76M | 200.89M | 998.7K | 833.6K |
| Gross Profit | 37.10M | 42.41M | 670.8K | 559.9K |
| Operating Income | -270,611,724 | -278,375,301 | 220.6K | 175.0K |
| Net Income | -333,524,860 | -343,093,352 | 158.4K | 135.2K |
| Gross Margin | 21.1% | 21.1% | 67.2% | 67.2% |
| Operating Margin | -154.0% | -138.6% | 22.1% | 21.0% |
| Profit Margin | -189.8% | -180.3% | 15.9% | 16.2% |
| Rev Growth | -12.5% | -12.5% | +6.7% | -0.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 41.2K | 41.2K | 1.27M | 1.32M |
| Total Equity | 787.5K | 787.5K | 1.77M | 1.97M |
| D/E Ratio | 0.05 | 0.05 | 0.71 | 0.67 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -260,505,031 | -282,866,361 | 317.7K | 242.4K |
| Free Cash Flow | — | — | 143.5K | 109.6K |